Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

OptimizeRx (OPRX) Income from Continuing Operations (2016 - 2026)

OptimizeRx's Income from Continuing Operations history spans 16 years, with the latest figure at 5020000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 6535.9% to 5020000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 5132000.0, a 125.52% increase, with the full-year FY2025 number at 5132000.0, up 125.52% from a year prior.
  • Income from Continuing Operations hit 5020000.0 in Q4 2025 for OptimizeRx, up from 779000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for OPRX hit a ceiling of 5020000.0 in Q4 2025 and a floor of 11740000.0 in Q4 2023.
  • Historically, Income from Continuing Operations has averaged 2560068.05 across 5 years, with a median of 2532000.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 8790.01% in 2022 and later skyrocketed 6535.9% in 2025.
  • Tracing OPRX's Income from Continuing Operations over 5 years: stood at 623462.0 in 2021, then crashed by 152.26% to 325836.0 in 2022, then tumbled by 3503.04% to 11740000.0 in 2023, then surged by 99.34% to 78000.0 in 2024, then skyrocketed by 6535.9% to 5020000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for OPRX at 5020000.0 in Q4 2025, 779000.0 in Q3 2025, and 1532000.0 in Q2 2025.